Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents

Jianjun Chen, Sunjoo Ahn, Jin Wang, Yan Lu, James T. Dalton, Duane Miller, Wei Li

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Novel ABI-III compounds were designed and synthesized based on our previously reported ABI-I and ABI-II analogues. ABI-III compounds are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compound having an average IC50 value of 3.8 nM. They are not substrate of Pgp and thus may effectively overcome Pgpmediated multidrug resistance. ABI-III analogues maintain their mechanisms of action by inhibition of tubulin polymerization.

Original languageEnglish (US)
Pages (from-to)7285-7289
Number of pages5
JournalJournal of Medicinal Chemistry
Volume55
Issue number16
DOIs
StatePublished - Aug 23 2012

Fingerprint

Multiple Drug Resistance
Tubulin
Polymerization
Inhibitory Concentration 50
Melanoma
Prostatic Neoplasms
Cell Line
imidazole

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. / Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane; Li, Wei.

In: Journal of Medicinal Chemistry, Vol. 55, No. 16, 23.08.2012, p. 7285-7289.

Research output: Contribution to journalArticle

@article{9e12b8e644474f98936973b62695d3fb,
title = "Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents",
abstract = "Novel ABI-III compounds were designed and synthesized based on our previously reported ABI-I and ABI-II analogues. ABI-III compounds are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compound having an average IC50 value of 3.8 nM. They are not substrate of Pgp and thus may effectively overcome Pgpmediated multidrug resistance. ABI-III analogues maintain their mechanisms of action by inhibition of tubulin polymerization.",
author = "Jianjun Chen and Sunjoo Ahn and Jin Wang and Yan Lu and Dalton, {James T.} and Duane Miller and Wei Li",
year = "2012",
month = "8",
day = "23",
doi = "10.1021/jm300564b",
language = "English (US)",
volume = "55",
pages = "7285--7289",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents

AU - Chen, Jianjun

AU - Ahn, Sunjoo

AU - Wang, Jin

AU - Lu, Yan

AU - Dalton, James T.

AU - Miller, Duane

AU - Li, Wei

PY - 2012/8/23

Y1 - 2012/8/23

N2 - Novel ABI-III compounds were designed and synthesized based on our previously reported ABI-I and ABI-II analogues. ABI-III compounds are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compound having an average IC50 value of 3.8 nM. They are not substrate of Pgp and thus may effectively overcome Pgpmediated multidrug resistance. ABI-III analogues maintain their mechanisms of action by inhibition of tubulin polymerization.

AB - Novel ABI-III compounds were designed and synthesized based on our previously reported ABI-I and ABI-II analogues. ABI-III compounds are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compound having an average IC50 value of 3.8 nM. They are not substrate of Pgp and thus may effectively overcome Pgpmediated multidrug resistance. ABI-III analogues maintain their mechanisms of action by inhibition of tubulin polymerization.

UR - http://www.scopus.com/inward/record.url?scp=84866943691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866943691&partnerID=8YFLogxK

U2 - 10.1021/jm300564b

DO - 10.1021/jm300564b

M3 - Article

VL - 55

SP - 7285

EP - 7289

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -